|
Administration
May be taken with or without food.
|
|
Contraindications
Hypersensitivity to abacavir. Patients who are positive for HLA-B*57:01 allele. Moderate to severe hepatic impairment. Lactation.
|
|
Special Precautions
Patient w/ risk factors for liver disease (e.g. obesity) and those w/ risk factors for coronary heart disease (e.g. HTN, DM, smoking). Renal or mild hepatic impairment. Pregnancy. Monitoring Parameters Monitor blood lipids and glucose reference.
|
|
Adverse Reactions
Fever, rash, cough, dyspnoea, lethargy, malaise, headache, myalgia, GI disturbances, particularly nausea, vomiting, diarrhoea and abdominal pain; pancreatitis and elevated liver enzyme values, osteonecrosis, immune reconstitution syndrome, MI, lipodystrophy syndrome. Rarely, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Potentially Fatal: Serious and fatal hypersensitivity reactions w/ multiple organ involvement, lactic acidosis and severe hepatomegaly w/ steatosis. |
|
Drug Interactions
Decreased serum concentrations of methadone. Slightly decreased plasma concentration w/ potent enzymatic inducers (e.g. rifampicin, phenobarbital, phenytoin). Ribavirin may enhance the hepatotoxic effect of nucleoside reverse transcriptase inhibitors.
|
|
CIMS Class
|
|
ATC Classification
J05AF06 - abacavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
|
Sign Out
